 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...75767778798081828384858687» |
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: PILOTE: Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=777, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2017 --> Dec 2017
- |||| Prolia (denosumab) / Amgen
Trial primary completion date: Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis (clinicaltrials.gov) - Oct 13, 2017
P3, N=150, Not yet recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2017 --> Dec 2017 Trial primary completion date: May 2020 --> Jan 2025
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, risedronate / Generic mfg., raloxifene hydrochloride / Generic mfg.
Journal: Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. (Pubmed Central) - Oct 12, 2017
Patients initiating injectable therapies had greater persistence and compliance at 2 years than those initiating oral therapies. Patients initiating an every-6-month injection had significantly higher persistence compared with those initiating more frequently dosed (e.g., daily and weekly) oral or injectable agents.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab Versus Bisphosphonates (Alendronate) in GIOP (clinicaltrials.gov) - Oct 11, 2017
P4, N=220, Recruiting, Sponsor: Tuen Mun Hospital
Patients initiating an every-6-month injection had significantly higher persistence compared with those initiating more frequently dosed (e.g., daily and weekly) oral or injectable agents. Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (clinicaltrials.gov) - Oct 9, 2017
P3, N=667, Completed, Sponsor: Daiichi Sankyo, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Prolia (denosumab) / Amgen
New P4 trial: Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 (clinicaltrials.gov) - Oct 4, 2017
P4, N=150, Not yet recruiting, Sponsor: Amgen
- |||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - Sep 26, 2017
P, N=75, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen
Enrollment closed, Metastases: Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid (clinicaltrials.gov) - Sep 25, 2017
P1, N=24, Active, not recruiting, Sponsor: OPKO Ireland Global Holdings Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen
Trial primary completion date, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Sep 18, 2017
P2, N=45, Active, not recruiting, Sponsor: Hope Rugo, MD
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Oct 2014
- ||||| Prolia (denosumab) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: KEYPAD: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (clinicaltrials.gov) - Sep 11, 2017
P2, N=70, Not yet recruiting, Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab for the Treatment of Adult LCH (clinicaltrials.gov) - Aug 31, 2017
P2, N=12, Recruiting, Sponsor: Hellenic Society for the Study of Bone Metabolism
- | Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
Review, Journal: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. (Pubmed Central) - Aug 31, 2017
While denosumab was found to reduce fractures, long-term survival data are still required...Recommendations are not meant to restrict such use of bone-modifying agents in these situations. Additional information at www.asco.org/breast-cancer-adjuvant-bisphosphonates-guideline , www.asco.org/guidelineswiki , https://www.cancercareontario.ca/guidelines-advice/types-of-cancer/breast .
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial, IO biomarker: Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone (clinicaltrials.gov) - Aug 22, 2017
P3, N=30, Recruiting, Sponsor: Hebei Medical University Third Hospital
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date, Trial primary completion date: Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders (clinicaltrials.gov) - Aug 21, 2017
P1/2, N=24, Not yet recruiting, Sponsor: Indiana University
Additional information at www.asco.org/breast-cancer-adjuvant-bisphosphonates-guideline , www.asco.org/guidelineswiki , https://www.cancercareontario.ca/guidelines-advice/types-of-cancer/breast . Initiation date: Jun 2017 --> Aug 2019 | Trial primary completion date: Jun 2018 --> Jun 2021
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Effect of Denosumab in Erosion Healing in RA (clinicaltrials.gov) - Aug 2, 2017
P2, N=110, Recruiting, Sponsor: Chinese University of Hong Kong
- | Xtandi (enzalutamide) / Pfizer, Astellas, Prolia (denosumab) / Amgen
Enrollment change, Trial termination, Trial primary completion date: Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=1, Terminated, Sponsor: University of Hawaii
Initiation date: Jun 2017 --> Aug 2019 | Trial primary completion date: Jun 2018 --> Jun 2021 N=30 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Sep 2016; Low accruals
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: Edward Fox
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (clinicaltrials.gov) - Jul 11, 2017
P3, N=795, Completed, Sponsor: Amgen
N=30 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Sep 2016; Low accruals Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Xofigo (radium Ra-223 dichloride) / Bayer
Trial primary completion date, Combination therapy, Metastases: Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer (clinicaltrials.gov) - Jul 11, 2017
P2, N=36, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2018 --> Feb 2019
- | Prolia (denosumab) / Amgen
Enrollment open: DENOCINA: Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. (clinicaltrials.gov) - Jun 27, 2017
P3, N=60, Enrolling by invitation, Sponsor: Peter Vestergaard
Trial primary completion date: Feb 2018 --> Feb 2019 Not yet recruiting --> Enrolling by invitation
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, risedronate / Generic mfg.
Journal: Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. (Pubmed Central) - Jun 22, 2017
ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis...ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women...ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
- ||||||| Prolia (denosumab) / Amgen
Trial completion: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis (clinicaltrials.gov) - Jun 8, 2017
P3, N=7808, Completed, Sponsor: Amgen
(Grade: weak recommendation; low-quality evidence). Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo, Xalkori (crizotinib) / Pfizer
Journal: Ovarian stimulation in young adult cancer survivors on targeted cancer therapies. (Pubmed Central) - Jun 7, 2017
Active, not recruiting --> Completed Successful fertility treatments are possible in the context of exposure to crizotinib and denosumab.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Benign Tumours of the Spine: Has new Chemotherapy and Interventional Radiology Changed the Treatment Paradigm? (Pubmed Central) - Jun 2, 2017
Most of the data are still emerging and further research is desirable. Close collaboration between the different specialists managing these pathologies is crucial.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (clinicaltrials.gov) - Jun 2, 2017
P4, N=15, Recruiting, Sponsor: Amgen
Close collaboration between the different specialists managing these pathologies is crucial. Trial primary completion date: May 2017 --> Feb 2018
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy (clinicaltrials.gov) - Jun 1, 2017
P3, N=7, Recruiting, Sponsor: Western University of Health Sciences
- |||||||||| Prolia (denosumab) / Amgen
New P3 trial: Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis (clinicaltrials.gov) - May 24, 2017
P3, N=150, Not yet recruiting, Sponsor: Amgen
- ||||| Prolia (denosumab) / Amgen, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, Checkpoint inhibition: CHARLI: Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - May 22, 2017
P1/2, N=72, Not yet recruiting, Sponsor: Australia and New Zealand Melanoma Trials Group
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, HEOR: Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis (clinicaltrials.gov) - May 16, 2017
P=N/A, N=236, Recruiting, Sponsor: Shaare Zedek Medical Center
Trial primary completion date: May 2017 --> Feb 2018 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: The Efficacy of Denosumab in Active Crohn's Disease (clinicaltrials.gov) - May 5, 2017
P1/2, N=30, Recruiting, Sponsor: University of Manitoba
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Feb 2018
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty (clinicaltrials.gov) - May 4, 2017
P2, N=30, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Trial primary completion date: Feb 2016 --> Feb 2018 Trial primary completion date: Jan 2015 --> Dec 2019
- |||| Prolia (denosumab) / Amgen
Trial primary completion date, Metastases: SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) - Apr 25, 2017
P3, N=1000, Recruiting, Sponsor: European Thoracic Oncology Platform
Trial primary completion date: Jan 2015 --> Dec 2019 Trial primary completion date: Apr 2019 --> Sep 2019
- | Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
Journal: Use of denosumab in recurrent chondroblastoma of the squamous temporal bone: a case report. (Pubmed Central) - Apr 13, 2017
Denosumab, a monoclonal antibody, has been demonstrated to inhibit the growth of giant cell tumors. We report a case of recurrent chondroblastoma of the squamous temporal bone that is currently suppressed with denosumab.
- Prolia (denosumab) / Amgen
Trial primary completion date, Metastases: Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid (clinicaltrials.gov) - Apr 13, 2017
P1, N=24, Recruiting, Sponsor: OPKO Ireland Global Holdings Ltd.
We report a case of recurrent chondroblastoma of the squamous temporal bone that is currently suppressed with denosumab. Trial primary completion date: Jan 2017 --> Dec 2018
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: DOHA: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis (clinicaltrials.gov) - Apr 12, 2017
P3, N=20, Not yet recruiting, Sponsor: Hamad Medical Corporation
Trial primary completion date: Jan 2017 --> Dec 2018 Initiation date: Apr 2017 --> Jul 2017
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Trial initiation date: Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty (clinicaltrials.gov) - Apr 7, 2017
P2, N=64, Completed, Sponsor: Hans Mallmin
Initiation date: Apr 2017 --> Jul 2017 Active, not recruiting --> Completed | Initiation date: Mar 2012 --> Aug 2012
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions (clinicaltrials.gov) - Apr 7, 2017
P2, N=20, Recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | Initiation date: Mar 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Tumor cell: Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells (clinicaltrials.gov) - Apr 1, 2017
P2, N=42, Recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab and Male Infertility: a RCT (clinicaltrials.gov) - Mar 27, 2017
P2, N=95, Recruiting, Sponsor: Martin Blomberg Jensen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Osteoclast Inhibition and Bone Formation (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=81, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (clinicaltrials.gov) - Mar 23, 2017
P4, N=60, Recruiting, Sponsor: Aarhus University Hospital
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Phase classification, Trial initiation date, Trial primary completion date: EDRPBLFHR: Longjohn Amgen Study - Effect of Denosumab... (clinicaltrials.gov) - Mar 17, 2017
P1, N=80, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Phase classification: PN/A --> P1 | Initiation date: Jun 2016 --> Feb 2017 | Trial primary completion date: Jul 2017 --> Dec 2017
- Prolia (denosumab) / Amgen
Phase classification: The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury (clinicaltrials.gov) - Mar 3, 2017
P4, N=32, Not yet recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P1 | Initiation date: Jun 2016 --> Feb 2017 | Trial primary completion date: Jul 2017 --> Dec 2017 Phase classification: P2 --> P4
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial, Tumor cell: Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells (clinicaltrials.gov) - Mar 3, 2017
P2, N=42, Not yet recruiting, Sponsor: Northwestern University
- |||| Prolia (denosumab) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov) - Feb 23, 2017
P2, N=778, Recruiting, Sponsor: German Breast Group
Phase classification: P2 --> P4 Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Dec 2018
- |||| Prolia (denosumab) / Amgen
Enrollment open: A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency (clinicaltrials.gov) - Feb 20, 2017
P2, N=55, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Phase classification: PILOTE: Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=777, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Phase classification: P4 --> P=N/A
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment open: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Feb 14, 2017
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P4 --> P=N/A Active, not recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment closed, Enrollment change: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Feb 11, 2017
P2, N=6, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=35 --> 6
- | Prolia (denosumab) / Amgen
Phase classification: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Feb 8, 2017
P=N/A, N=575462, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=35 --> 6 Phase classification: P4 --> P=N/A